Exchange: NYSE·Updated 07:30 PM EDT

RMD News

News
all
press releases
ResMed Breaks Above 200-Day Moving Average - Bullish for RMD
In trading on Wednesday, shares of ResMed Inc. (Symbol: RMD) crossed above their 200 day moving average of $225.46, changing hands as high as $228.75 per share. ResMed Inc. shares are currently trading up about 2.7% on the day. The chart below shows the one year performance of...
Nasdaq News: Markets
ResMed Breaks Above 200-Day Moving Average - Bullish for RMD
In trading on Wednesday, shares of ResMed Inc. (Symbol: RMD) crossed above their 200 day moving average of $225.46, changing hands as high as $228.75 per share. ResMed Inc. shares are currently trading up about 2.7% on the day. The chart below shows the one year performance of...
Nasdaq News: Markets
More News
Is This the Right Time to Retain Resmed Stock in Your Portfolio?
RMD's software portfolio optimization, mask innovation and solid financial health support growth, though macro pressures and competition pose risks.
Zacks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD PR Newswire NEW YORK, Aug. 27, 2026 NEW YORK, Aug. 27, 2026 /PRNewswire/ --Pomerantz LLP is...
PR Newswire
ResMed (RMD) Q4 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists
INGN cuts its 2026 revenue outlook as U.S. channel pressure weighs, while international growth, new products and cost control offer support.
Zacks
Should Investors Buy Inogen as Low Valuation Meets Execution Risk?
Inogen's steep sales-multiple discount, improving margins and firm international demand clash with U.S. sales and rental weakness.
Zacks
Resmed's stock falls by 7% on soft FY27 outlook
Resmed's stock falls by 7% on soft FY27 outlook...
Yahoo! Finance: News
RMD Stock Down Despite Q4 Earnings Beat, Revenues Rise Y/Y
Resmed's Q4 earnings and revenues beat estimates, but shares fall as fiscal 2027 revenue guidance trails the consensus mark.
Zacks
Trade Desk Posts Downbeat Q2 Results, Joins Sezzle, Resmed, Ouster And Other Big Stocks Moving Lower In Friday's Pre-Market Session
US stock futures mixed, Nasdaq 100 futures up 100 points. Trade Desk Inc shares down 27.7% after weak Q2 results. Other stocks also lower premarket.read more...
Benzinga
ResMed (RMD) Q4 Earnings and Revenues Top Estimates
ResMed (RMD) delivered earnings and revenue surprises of +1.72% and +0.17%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.